Revelation Biosciences Inc (REVB) News

Form S-3 - Registration statement under Securities Act of 1933

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of...

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company...

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing...

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral...

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing...

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

– Oral presentation in addition to poster presentation announced January 30, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or...

Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...